|
Pharmexcil and Mexican Consulate join hands to chart new avenues for Indian pharma expansion
|
|
Shardul Nautiyal, Mumbai
August 12 , 2025
|
|
|
In a bid to unlock new growth prospects for Indian pharmaceutical companies and deepen cross-border industry ties with Mexico, the Consulate of Mexico in Mumbai has joined hands with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) for further collaborations and raise awareness about the Mexican pharmaceutical market, which is increasingly seen as a promising destination for Indian pharmaceutical exports, technology collaborations, and manufacturing partnerships.
This is a welcome development as Mexico has plans to increase by the national content of 15% in global value chains in sectors like pharmaceutical and vaccine production. Vaccines made in Mexico will promote the development of pharmaceutical manufacturing processes and local packaging with emphasis on advanced biotechnology.
It also plans to reduce from 2.6 to 1 year the time needed to set up an investment: 50% fewer procedures and requirements, with a digital single window for investors. There are plans to promote investments with ESG practices such as water reuse, investment in clean energy with backup, solid waste, solid waste management systems, and community impact actions.
As a part of the initiative a special virtual event has been announced titled “Mexico: Expansion Opportunities for the Indian Pharmaceutical Industry.” scheduled August 14, 2025 at 7:00 pm IST, the event will be conducted in a hybrid format, enabling wide participation from across India.
“With Mexico serving as a gateway to Latin American markets and possessing a robust domestic demand for affordable healthcare solutions, Indian pharma companies are being encouraged to explore fresh business opportunities in the region. This event offers a valuable opportunity for Indian pharmaceutical companies already operating in Mexico, as well as those exploring expansion into the region. We encourage all interested members to actively participate in this virtual meet,” said Raja Bhanu, director general, Pharmexcil, highlighting the relevance of the initiative in today’s globalized healthcare landscape.
According to Pharmexcil, the virtual session will bring together key stakeholders from both nations, fostering direct interaction between Indian and Mexican pharmaceutical companies. The objective is not only to share market intelligence but also to pave the way for meaningful business collaborations, regulatory understanding, and long-term partnerships.
Mexico also plans to attract 2 billion USD of annual investment in clinical research with 15% increase in the manufacturing of supplies, packaging, labels, pharmaceutical chemicals, blood derivatives, generic medications, machinery, connectable medical devices, glycosylated haemoglobin analyzer, hospital clothing, surgical instruments, prosthetics and osteosynthesis material, intraocular lenses for ophthalmology, inputs for peritoneal dialysis (dialysis bags), aseptic and antiseptic materials, and hospital furniture.
Mexico plans to produce 90% of SRP-V, Rotavirus, influenza vaccines within Mexico’s National Vaccination Plan and achieve a mixed investment project to produce generics for diabetes and hypertension like liraglutide, dapagliflozin, and valsartan.
Mexico action plan for (2025 – 2030) includes key projects like mRNA technology vaccine factory. It has plans for private investment in the first mRNA technology vaccine production plant in Mexico for national consumption and export in Felipe Ángeles International Airport (AIFA) corridor and also has plans for joint venture for diabetes generics.
Public and private sectors have initiated coordinated efforts to establish the AIFA corridor as a development hub for data centres. This initiative seeks to capitalize on existing infrastructure to attract an estimated USD 9.2 billion in investment over the next five years, positioning Mexico as a key node in the regional digital economy.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|